Handbook of Analytical Separations

SEPARATION METHODS IN DRUG SYNTHESIS AND PURIFICATION



Second Edition

Edited by

KLÁRA L. VALKÓ Bio-Mimetic Chromatography Ltd Business & Technology Center Bessemer Drive, Stevenage Herts, United Kingdom



Contents

Con	tribu	tors	xi
Prefe	асе		xiii
1.	HP		1
	Pav	el Jandera	
	1.1	Fundamentals of high-performance liquid chromatography	1
	1.2	High-performance liquid chromatography separation media	11
	1.3		24
		Method development and optimization of separation conditions	58
	Refe	erences	84
2.	Fas	t-generic HPLC methods	93
	lan	M. Mutton	
	2.1	Introduction	93
	2.2	Theory	94
	2.3	Strategy for production of fast gradients	96
	2.4	Fast gradients in practice	105
	2.5	Conclusions	108
	Refe	erences	108
3.	Ad	vances in capillary electrochromatography	113
	Jose	é Luís Dores-Sousa, Jelle De Vos, Debby Mangelings	
	and	Sebastiaan Eeltink	
	3.1	Introduction	113
	3.2	The electroosmotic flow	115
	3.3	Separation efficiency and kinetic performance limits	118
	3.4	Retention	122
	3.5	Instrument setup	124
	3.6	Column technology	126
	3.7	(Bio)pharmaceutical and biochemical applications	129
	3 <i>.</i> 8	Concluding remarks	134
	List	of abbreviations and symbols	134
	Ack	nowledgements	135
	Refe	erences	135

•

4.		pled chromatography—mass spectrometry techniques the analysis of combinatorial libraries	143
	Stev	e Lane	
	4.1	Introduction	143
	4.2	LC/MS analysis of high-throughput parallel synthesis libraries	148
	4.3	Example for monitoring the rehearsal phase of the synthesis of	
		a solid-phase library	157
	4.4	LC/UV/MS as a prescreen for Autoprep solution phase	158
	4.5	Assisted automated LC/MS analysis	162
	4.6	The analysis of split-pool combinatorial libraries	164
	4.7	Industrialization of the process	175
	4.8	Conclusions and future	191
	Refe	ences	193
5.	Exp	erimental design-based optimization strategies for	
	chro	matographic and capillary electrophoretic separations	197
	Joha	n Viaene and Yvan Vander Heyden	
	5.1	Introduction	197
	5.2	Main factors affecting separation	200
	5.3	Responses and response functions	200
	5.4	Univariate optimization strategies	205
	5.5	Simplex sequential approach	208
	5.6	Factorial methods	213
	5.7	Multicriteria decision-making methods	265
	5.8	Peculiarities of optimizing separations: optimizing resolution	270
	5.9	Automating the entire process: expert systems and knowledge-based	
		systems	272
	5.10	Transfer of optimized capillary electrophoresis methods	273
	5.11	Conclusions	274
	Refe	rences	274
6.	Con	nputer-aided HPLC method development for quality	
		trol of complex drug mixtures — An application	
	exa	mple for DryLab	277
		na Katsialevich, Hans-Jürgen Rieger, Imre Molnár Arnold Zöldhegyi	
			770
	6.1	Introduction	278 191
	6.2	Experimental part	281
	6.3	Method development using the DryLab4 software	285

	6.4	Summary	301
	Ackı	nowledgements	302
	Refe	rences	302
7.	The	flexible application of automated preparative purification	
	plat	forms within drug discovery	307
	Jeni	nifer Kingston, Neil Sumner, Katie Proctor and Elisabetta Chiarparin	
	7.1	Introduction	307
	7.2	Reverse-phase high-performance liquid chromatography as a robust	
		chromatographic tool	310
	7.3	HPLC purification within drug discovery	317
	7.4	Evolution of supercritical fluid chromatography as a robust purification	
		platform	325
	7.5	Multi-parallel synthesis purification processes at AstraZeneca	340
	7.6	Flexible use of HPLC and SFC as orthogonal separation techniques	344
	7.7	Conclusions	346
	Refe	rences	346
	.		
8.	as a	ategies for the development of process chromatography a unit operation for the pharmaceutical industry w Katti	349
8.	as a Dre	a unit operation for the pharmaceutical industry	349 349
8.	as a Drev 8.1	a unit operation for the pharmaceutical industry w Katti Introduction	
8.	as a Drev 8.1 8.2	a unit operation for the pharmaceutical industry w Katti Introduction 2. The process development cycle	349
8.	as a Dre ¹ 8.1 8.2 8.3	a unit operation for the pharmaceutical industry w Katti Introduction The process development cycle Chromatographic unit operations	349 359
8.	as a Drev 8.1 8.2 8.3 8.4	a unit operation for the pharmaceutical industry w Katti Introduction The process development cycle Chromatographic unit operations Discovery experiment stage	349 359 367
8.	as a Drev 8.1 8.2 8.3 8.4 8.5	a unit operation for the pharmaceutical industry w Katti Introduction The process development cycle Chromatographic unit operations	349 359 367 371
8.	as a Drev 8.1 8.2 8.3 8.4 8.5 8.6	 a unit operation for the pharmaceutical industry w Katti Introduction The process development cycle Chromatographic unit operations Discovery experiment stage Development stage 	349 359 367 371 382
8.	as a Drev 8.1 8.2 8.3 8.4 8.5 8.6 8.7	 a unit operation for the pharmaceutical industry w Katti Introduction The process development cycle Chromatographic unit operations Discovery experiment stage Development stage Modes of chromatography 	349 359 367 371 382 383
8.	as a Drev 8.1 8.2 8.3 8.4 8.5 8.6 8.6 8.7 8.8	 a unit operation for the pharmaceutical industry k Katti Introduction The process development cycle Chromatographic unit operations Discovery experiment stage Development stage Modes of chromatography Overloaded elution chromatography-isocratic mode 	349 359 367 371 382 383 384
8.	as a Drev 8.1 8.2 8.3 8.4 8.5 8.6 8.7 8.6 8.7 8.8	 a unit operation for the pharmaceutical industry k Katti Introduction The process development cycle Chromatographic unit operations Discovery experiment stage Development stage Modes of chromatography Overloaded elution chromatography-isocratic mode Economics of overloaded elution chromatography Simulated moving bed chromatography 	349 359 367 371 382 383 384 403
8.	as a Drev 8.1 8.2 8.3 8.4 8.5 8.6 8.7 8.8 8.9 8.10	 a unit operation for the pharmaceutical industry k Katti Introduction The process development cycle Chromatographic unit operations Discovery experiment stage Development stage Modes of chromatography Overloaded elution chromatography-isocratic mode Economics of overloaded elution chromatography 	349 359 367 371 382 383 384 403 417
8.	as a Drev 8.1 8.2 8.3 8.4 8.5 8.6 8.7 8.6 8.7 8.6 8.9 8.10 8.11	 a unit operation for the pharmaceutical industry k Katti Introduction The process development cycle Chromatographic unit operations Discovery experiment stage Development stage Modes of chromatography Overloaded elution chromatography-isocratic mode Economics of overloaded elution chromatography Simulated moving bed chromatography Chromatography techniques make a comes back 	349 359 367 371 382 383 384 403 417 426
8.	as a Dree 8.1 8.2 8.3 8.4 8.5 8.4 8.5 8.6 8.7 8.7 8.8 8.9 8.10 8.11 8.12	 a unit operation for the pharmaceutical industry w Katti Introduction The process development cycle Chromatographic unit operations Discovery experiment stage Development stage Modes of chromatography Overloaded elution chromatography-isocratic mode Economics of overloaded elution chromatography Simulated moving bed chromatography Chromatography techniques make a comes back Safety and environmental 	349 359 367 371 382 383 384 403 417 426 428
8.	as a Drev 8.1 8.2 8.3 8.4 8.5 8.6 8.7 8.8 8.7 8.8 8.10 8.11 8.12 8.13	 a unit operation for the pharmaceutical industry k Katti Introduction The process development cycle Chromatographic unit operations Discovery experiment stage Development stage Modes of chromatography Overloaded elution chromatography-isocratic mode Economics of overloaded elution chromatography Simulated moving bed chromatography Chromatography techniques make a comes back Safety and environmental Regulatory and compliance 	349 359 367 371 382 383 384 403 417 426 428 436
8.	as a Drev 8.1 8.2 8.3 8.4 8.5 8.6 8.7 8.6 8.7 8.6 8.10 8.11 8.12 8.13 List	 a unit operation for the pharmaceutical industry a Katti Introduction The process development cycle Chromatographic unit operations Discovery experiment stage Development stage Modes of chromatography Overloaded elution chromatography-isocratic mode Economics of overloaded elution chromatography Simulated moving bed chromatography Chromatography techniques make a comes back Safety and environmental Regulatory and compliance Conclusion 	349 359 367 371 382 383 384 403 417 426 428 436 439

vii

Contents

9.	chro	ent developments in liquid and supercritical fluid omatographic enantioseparations by Mangelings, Sebastiaan Eeltink and Yvan Vander Heyden	453
		Stereochemistry in a pharmaceutical environment Enantioseparations of racemates in liquid chromatography and	453
		sub/supercritical fluid chromatography	454
	9.3	Scope and aims	458
	9.4	Direct enantioseparations with chiral mobile phase additives	458
	9.5	Direct enantioseparations: chiral stationary phases	459
	9.6	Conclusions	503
	Abbi	reviations	505
	Refe	rences	506
10.		s and pharmaceutical applications of thin-layer	
	chro	omatography	523
	Hub	a Kalász, Mária Báthori and Klára L. Valkó	
	10.1	Planar chromatography	523
	10.2	The components of the planar stationary phase	535
	10.3	Mobile phases for thin-layer chromatography	546
	10.4	The chambers	548
		Detection	555
	10.6	Application of thin-layer chromatography in pharmaceutical and forensic analysis	566
	107	Future developments, Quo Vadis thin-layer chromatography	577
		iowledgements	578
		rences	578
11.	Rec	ent advances in quantitative structure-retention	
		tionships	587
	Rom	an Kaliszan	
	11.1	Introduction	587
	11.2	Strategy of quantitative structure-retention relationship research	589
	11.3	Retention prediction	601
	11.4	Molecular mechanism of retention in view of quantitative	
		structure—retention relationship	608
		Chromatographic methods of determination of hydrophobicity	613
	11.6	Applications of quantitative structure-retention relationship in	
		molecular pharmacology and rational drug design	616

	Contents	ix
	11.7 Concluding remarks	621
	References	622
	herences	
12.	Capillary electrophoresis for drug analysis and physicochemical characterization	633
	Susana Amézqueta, Xavier Subirats, Elisabet Fuguet, Clara Ràfols and Martí Rosés	
	12.1 Introduction to capillary electrophoresis	633
	12.2 Buffers in capillary electrophoresis	636
	12.3 Capillary zone electrophoresis	640
	12.4 Nonaqueous capillary electrophoresis	649
	12.5 Introduction to micellar electrokinetic chromatography12.6 Introduction to microemulsion and liposome electrokinetic	657
	chromatography	660
	References	663
	of physicochemical and biomimetic properties to model	
	in vivo drug distribution in support of early drug discovery Klára L. Valkó	667
	in vivo drug distribution in support of early drug discovery Klára L. Valkó	
	 in vivo drug distribution in support of early drug discovery Klára L. Valkó 13.1 Introduction 13.2 Measurements of compound lipophilicity using chromatography 	667 667 669
	 in vivo drug distribution in support of early drug discovery Klára L. Valkó 13.1 Introduction 13.2 Measurements of compound lipophilicity using chromatography 13.3 Measurement of membrane binding by immobilized artificial membrane high-performance liquid chromatography 	667
	 in vivo drug distribution in support of early drug discovery Klára L. Valkó 13.1 Introduction 13.2 Measurements of compound lipophilicity using chromatography 13.3 Measurement of membrane binding by immobilized artificial membrane high-performance liquid chromatography 13.4 Measurement of drug-protein binding constants by high-performance 	667 669
	 in vivo drug distribution in support of early drug discovery Klára L. Valkó 13.1 Introduction 13.2 Measurements of compound lipophilicity using chromatography 13.3 Measurement of membrane binding by immobilized artificial membrane high-performance liquid chromatography 13.4 Measurement of drug-protein binding constants by high-performance liquid chromatography 13.5 Measurements of solubility by high-performance liquid chromatograph 	667 669 689 695
	 in vivo drug distribution in support of early drug discovery Klára L. Valkó 13.1 Introduction 13.2 Measurements of compound lipophilicity using chromatography 13.3 Measurement of membrane binding by immobilized artificial membrane high-performance liquid chromatography 13.4 Measurement of drug-protein binding constants by high-performance liquid chromatography 13.5 Measurements of solubility by high-performance liquid chromatography 13.6 Measurement of acid-base character by high-performance liquid 	667 669 689 695
	 in vivo drug distribution in support of early drug discovery Klára L. Valkó 13.1 Introduction 13.2 Measurements of compound lipophilicity using chromatography 13.3 Measurement of membrane binding by immobilized artificial membrane high-performance liquid chromatography 13.4 Measurement of drug-protein binding constants by high-performance liquid chromatography 13.5 Measurements of solubility by high-performance liquid chromatography 13.6 Measurement of acid-base character by high-performance liquid chromatography 	667 669 689 695 y 702
	 in vivo drug distribution in support of early drug discovery Klára L. Valkó 13.1 Introduction 13.2 Measurements of compound lipophilicity using chromatography 13.3 Measurement of membrane binding by immobilized artificial membrane high-performance liquid chromatography 13.4 Measurement of drug-protein binding constants by high-performance liquid chromatography 13.5 Measurements of solubility by high-performance liquid chromatography 13.6 Measurement of acid-base character by high-performance liquid chromatography 13.7 Measurements of H-bond acidity, basicity and polarizability/dipolarity 	667 669 689 695 y 702
	 in vivo drug distribution in support of early drug discovery Klára L. Valkó 13.1 Introduction 13.2 Measurements of compound lipophilicity using chromatography 13.3 Measurement of membrane binding by immobilized artificial membrane high-performance liquid chromatography 13.4 Measurement of drug-protein binding constants by high-performance liquid chromatography 13.5 Measurements of solubility by high-performance liquid chromatography 13.6 Measurement of acid-base character by high-performance liquid chromatography 	667 669 689 695 y 702 710
	 in vivo drug distribution in support of early drug discovery Klára L. Valkó 13.1 Introduction 13.2 Measurements of compound lipophilicity using chromatography 13.3 Measurement of membrane binding by immobilized artificial membrane high-performance liquid chromatography 13.4 Measurement of drug-protein binding constants by high-performance liquid chromatography 13.5 Measurements of solubility by high-performance liquid chromatography 13.6 Measurement of acid-base character by high-performance liquid chromatography 13.7 Measurements of H-bond acidity, basicity and polarizability/dipolarity by high-performance liquid chromatography 	667 669 689 695 y 702 710 717

Index

759